Physician profile
John P Aey
NPI 1316949803
$7,601.15
in general payments reported to CMS, 2019-2025
23 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,163 · 2020: $774 · 2021: $1,060 · 2022: $774 · 2023: $870 · 2024: $652 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,285.38 | 2019-2022 | |
| Alcon Vision LLC | $1,258.40 | 2019-2025 | Rocklatan, Clareon Panoptix Pro, Clareon |
| New World Medical,INC. | $1,030.30 | 2020-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Abbvie INC. | $888.91 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $394.44 | 2019-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $333.41 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $206.48 | 2019-2021 | |
| Oyster Point Pharma, INC. | $197.43 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $174.87 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $152.60 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $139.08 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $131.85 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $71.10 | 2023-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Thea Pharma INC. | $68.42 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $50.82 | 2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $50.00 | 2022 | |
| Ocular Therapeutix, INC. | $37.68 | 2020-2023 | Dextenza |
| Dompe US, INC. | $34.39 | 2021-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $30.96 | 2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $25.63 | 2024 | Xdemvy |
| Shire North American Group INC | $16.37 | 2019 | |
| Medline Industries LP | $13.18 | 2021 | |
| Iridex Corporation | $9.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Aey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.